Komatsu R, Fujii R, Ogasawara T, Suzuki-Takahashi Y, Chen S, Sugishita Y
Int J Mol Sci. 2025; 26(3).
PMID: 39940918
PMC: 11817658.
DOI: 10.3390/ijms26031151.
Shanabag A, Armand J, Son E, Yang H
Exp Mol Med. 2025; 57(2):312-322.
PMID: 39930131
PMC: 11873051.
DOI: 10.1038/s12276-025-01395-3.
Schirripa A, Schoppe H, Nebenfuehr S, Zojer M, Klampfl T, Kugler V
iScience. 2025; 28(2):111697.
PMID: 39898030
PMC: 11787673.
DOI: 10.1016/j.isci.2024.111697.
Bobbitt J, Cuellar-Vite L, Weber-Bonk K, Yancey M, Majmudar P, Keri R
J Biol Chem. 2025; 301(2):108196.
PMID: 39826695
PMC: 11849632.
DOI: 10.1016/j.jbc.2025.108196.
Pellarin I, DallAcqua A, Favero A, Segatto I, Rossi V, Crestan N
Signal Transduct Target Ther. 2025; 10(1):11.
PMID: 39800748
PMC: 11734941.
DOI: 10.1038/s41392-024-02080-z.
Non-canonical CDK6 activity promotes cilia disassembly by suppressing axoneme polyglutamylation.
He K, Sun X, Chen C, Luc S, Robichaud J, Zhang Y
J Cell Biol. 2024; 224(2).
PMID: 39636239
PMC: 11619382.
DOI: 10.1083/jcb.202405170.
CDK6-mediated endothelial cell cycle acceleration drives arteriovenous malformations in hereditary hemorrhagic telangiectasia.
Dinakaran S, Qutaina S, Zhao H, Tang Y, Wang Z, Ruiz S
Nat Cardiovasc Res. 2024; 3(11):1301-1317.
PMID: 39487364
PMC: 11651362.
DOI: 10.1038/s44161-024-00550-9.
The G-S transition is promoted by Rb degradation via the E3 ligase UBR5.
Zhang S, Valenzuela L, Zatulovskiy E, Mangiante L, Curtis C, Skotheim J
Sci Adv. 2024; 10(43):eadq6858.
PMID: 39441926
PMC: 11498223.
DOI: 10.1126/sciadv.adq6858.
Mechanistic modeling of cell viability assays with lineage tracing.
Mutsuddy A, Huggins J, Amrit A, Erdem C, Calhoun J, Birtwistle M
bioRxiv. 2024; .
PMID: 39253474
PMC: 11383287.
DOI: 10.1101/2024.08.23.609433.
Identification of CDK4/6 Inhibitors as Small Molecule NLRP3 Inflammasome Activators that Facilitate IL-1β Secretion and T Cell Adjuvanticity.
Weiss A, Lopez 2nd M, Rosenberger M, Kim J, Shen J, Chen Q
J Med Chem. 2024; 67(17):14974-14985.
PMID: 39162654
PMC: 11736968.
DOI: 10.1021/acs.jmedchem.4c00516.
Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models.
Wu J, Wang J, OConnor T, Tzetzo S, Gurova K, Knudsen E
Mol Cancer Ther. 2024; 23(12):1801-1814.
PMID: 39148328
PMC: 11614708.
DOI: 10.1158/1535-7163.MCT-24-0369.
Single-cell total-RNA profiling unveils regulatory hubs of transcription factors.
Niu Y, Luo J, Zong C
Nat Commun. 2024; 15(1):5941.
PMID: 39009595
PMC: 11251146.
DOI: 10.1038/s41467-024-50291-3.
Genome-wide in vivo CRISPR screen identifies TGFβ3 as actionable biomarker of palbociclib resistance in triple negative breast cancer.
Poulet S, Dai M, Wang N, Yan G, Boudreault J, Daliah G
Mol Cancer. 2024; 23(1):118.
PMID: 38831405
PMC: 11145857.
DOI: 10.1186/s12943-024-02029-4.
Slower CDK4 and faster CDK2 activation in the cell cycle.
Zhang W, Liu Y, Jang H, Nussinov R
Structure. 2024; 32(8):1269-1280.e2.
PMID: 38703777
PMC: 11316634.
DOI: 10.1016/j.str.2024.04.012.
Kinase-inactivated CDK6 preserves the long-term functionality of adult hematopoietic stem cells.
Mayer I, Doma E, Klampfl T, Prchal-Murphy M, Kollmann S, Schirripa A
Blood. 2024; 144(2):156-170.
PMID: 38684032
PMC: 11302456.
DOI: 10.1182/blood.2023021985.
CDK4/6 inhibitors in lung cancer: current practice and future directions.
Lv S, Yang J, Lin J, Huang X, Zhao H, Zhao C
Eur Respir Rev. 2024; 33(171).
PMID: 38355149
PMC: 10865100.
DOI: 10.1183/16000617.0145-2023.
The yin and yang of chromosomal instability in prostate cancer.
Carceles-Cordon M, Orme J, Domingo-Domenech J, Rodriguez-Bravo V
Nat Rev Urol. 2024; 21(6):357-372.
PMID: 38307951
PMC: 11156566.
DOI: 10.1038/s41585-023-00845-9.
Serum-Induced Proliferation of Human Cardiac Stem Cells Is Modulated via TGFβRI/II and SMAD2/3.
Schmidt K, Hoving A, Kiani Zahrani S, Trevlopoulou K, Kaltschmidt B, Knabbe C
Int J Mol Sci. 2024; 25(2).
PMID: 38256034
PMC: 10815425.
DOI: 10.3390/ijms25020959.
The CDK4/6 inhibitor revolution - a game-changing era for breast cancer treatment.
Morrison L, Loibl S, Turner N
Nat Rev Clin Oncol. 2023; 21(2):89-105.
PMID: 38082107
DOI: 10.1038/s41571-023-00840-4.
Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity.
Zhang M, Kim S, Yang H
Nat Commun. 2023; 14(1):7847.
PMID: 38030655
PMC: 10687137.
DOI: 10.1038/s41467-023-43716-y.